卖什么
Graph Safety为药企和生物科技公司的药物警戒团队自动化不良事件录入、病例处理和汇总报告。
商业模式拆解
买家：谁掌握预算？
未核实Head of Pharmacovigilance / Drug Safety at pharma, biotech and CROs.
触发点：什么让他们现在购买？
未核实Rising case volumes and manual case-processing cost, plus regulatory pressure for inspection-ready, auditable safety operations.
工作流：什么输入变成什么输出？
Ingests safety cases from email, PDF, XML, APIs, literature and partner feeds, extracts patient/drug/event data, codes with MedDRA, dedupes, builds submission-ready cases, then generates E2B(R3) regulatory reports (report, signal detection, assure, comply modules rolling out Aug 2026 to Jan 2027).
经济账：省了什么，怎么收费？
Software platform; site claims 90% reduction in effort, 92% faster processing and 66% cost savings in pharmacovigilance operations.
渠道：怎么接触到客户？
Demo-led sales ('Talk to our team', 'See it in action'); offices in Pleasanton CA and Hyderabad.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-09-10 | A 轮 | $13.3M | Insight Partners (lead), Bessemer Venture Partners | entrackr.com |
| 2026-08-13 | A 轮 | 170억원 | K2 Investment Partners (lead), A.ventures, GY Investment (per Daum snippets) | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-13.